Batoclimab for Generalized Myasthenia Gravis

For the treatment of myasthenia gravis, the FDA recently approved efgartigimod and rozanolixizumab, both of which antagonize the neonatal fragment crystallizable receptor (FcRn), resulting in a reduction of circulating immunoglobulin G (IgG). To test the efficacy of batoclimab, an investigational anti-FcRn monoclonal antibody, researchers conducted an industry-funded, phase 3, randomized, double-blind, multicenter trial in China. The study included 131 patients (mean age, 44 years) with generalized myasthenia gravis who were positive for acetylcholine receptor (AChR) and/or muscle-specific kinase (MuSK) antibodies. They received 6 weekly subcutaneous injections of batoclimab or placebo. A second treatment cycle was given after ≥4 weeks to m…